RESEARCH
ctDNA in the Management of Resectable & Advanced Colorectal CancerA structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing in stage I-III CRC and selected patients with resected or ablated oligometastatic stage IV disease. (Onco Targets Ther)